FDA warns Premier Manufacturing over Tianaa tianeptine products sold as unapproved new drugs.
What happened
FDA reviewed labeling from an inspection of Atofil, LLC, from January 22 to 25, 2024, and found Premier Manufacturing offered “Tianaa Red,” “Tianaa White,” and “Tianaa Green” tianeptine products for sale in the U.S. FDA cited email blast promotional material linking to the company website as evidence the products are intended as drugs. FDA said the products are unapproved new drugs because there are no FDA-approved applications for them.
What FDA found
FDA considers the products drugs because their promotional labeling claims effects such as clarity, relaxation, and relief, showing they are intended to affect the body or treat disease.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)The products are “new drugs” because they are not generally recognized as safe and effective for their claimed uses.
FD&C Act section 201(p), 21 U.S.C. 321(p)The products were introduced or delivered for introduction into interstate commerce without an FDA-approved application.
FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)
What FDA wants
FDA asks the company to send a written response within 15 working days to CDER’s Office of Unapproved Drugs and Labeling Compliance describing steps to correct the violations, prevent recurrence, and related documentation, or explain with support why it believes it is not in violation.
Who should pay attention
- retailers and online sellers of Tianaa or tianeptine products
- distributors and brands buying tianeptine products from contract manufacturers
- companies making supplement-like products with drug claims
This is a summary. Read the original letter on fda.gov.